Vrije Universiteit Brussel Homepage VIB Homepage

Patents and spin-off

CMIM patents

Description Priority date(s) Priority Application number(s) Applicant Inventor(s)
African trypanosomiasis therapy with a nanobody-conjugated trypanolytic factor 6/10/2005 EP2005109300 VIB / VUB De Baetselier Patrick, Muyldermans Serge, Magez Stefan
Use of P-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas 19/09/2005 EP2005108577 VIB / VUB De Baetselier Patrick, Raes Geert, Hassanzadeh Ghassabeh Gholamreza
Treatment of EGFR dependent tumours 14/04/2005 EP2005102967 VIB / UGent / VUB Beyaert Rudi, Revets Hilde, Huang Lieven
Novel markers for alternatively activated macrophages 9/09/2003 EP20030102724 VIB / VUB Raes Geert, Hassanzadeh Ghassabeh Gholamreza, De Baetselier Patrick
The use of a polypeptide domain of SLPI to modulate the tumorigenic and metastatic potential of cancer cells 7/05/2003 EP20030101265 VIB / VUB Revets Hilde, De Baetselier Patrick, Devoogdt Nick, Hassanzadeh Ghassabeh Gholamreza
An immunomodulatory protein derived from trypanosomes and uses thereof 23/12/2002 EP20020080667 VIB / VUB Beschin Alain, De Baetselier Patrick
Novel immunoconjugates useful for treatment of tumours (Immunoconjugates) 3/01/2002; 9/07/2002 EP20020075048 VIB Revets Hilde, Cortez-Retamozo Virna, Muyldermans Serge, De Baetselier Patrick
Th1 inducing natural adjuvant for heterologous antigens 18/02/2000 EP20000200589 VIB Revets Hilde, Cornelis Pierre, De Baetselier Patrick
New uses of suppressive macrophage activation markers 30/11/1999 EP19990870245 Innogenetics Fransen Lucia, De Baetselier Patrick
TNF-derived peptides for use in treating oedema 14/08/1998; 18/09/1998; 21/10/1998 EP19980870180; EP19980870198; EP19980870222 Innogenetics Lucas Rudolf, De Baetselier Patrick, Pugin Jerome, Bloc Alain, Fansen Lucie
Peptides and nucleic acids derived from Eisenia Foetida and the use thereof 17/12/1997 EP19970203974 VIB De Baetselier Patrick, Beschin Alain
TNF-alpha muteins and a process for preparing them 3/02/1993 EP19930400262 Innogenetics Lucas Rudolf, De Baetselier Patrick, Fansen Lucia, Sablon Erwin

Back to top

Additional patents Serge Muyldermans (before 2003)

Description Priority date(s) Priority Application number(s) Applicant Inventor(s)
Method for cloning of variable domain sequences 21/12/2001 EP2001205100 VIB Muyldermans Serge
Mutant heavy chain antibodies (Functional heavy chain antibodies, fragments thereof and methods of production thereof) 24/10/2001 EP20010204037 VIB Muyldermans Serge
Recognition molecules interacting specifically with the active site or cleft of a target molecule 27/06/1996 EP1996201788 VIB Muyldermans Serge, Wyns Lode
Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes 25/04/1995 EP1995400932 VUB Hamers Raymond, Muyldermans Serge
Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae 29/04/1993; 19/05/1993; 15/07/1993 EP19930201239 EP19930201454 EP19930202079 Conopco / Unilever / VUB Hamers Raymond, Hamers-Castermans Cecile, Muyldermans Serge, Frenken Leon G, Verrips Cornelis T

Back to top

The VUB-VIB spin-off Ablynx

Ablynx, a biopharmaceutical company with headquarters in Ghent, Belgium, is engaged in the discovery and development of Nanobodies to treat a range of serious human diseases. Nanobodies are a novel class of antibody-derived therapeutic proteins. Because of their small size, unique structure and extreme stability, Nanobodies combine the advantages of conventional antibody therapeutics with the key features of small-molecule drugs.

The power of Ablynx's discovery platform has resulted in a Nanobody development candidate. Ablynx's lead programme, ALX-0081, became the first ever single domain antibody to enter clinical trials and Ablynx reported the final positive results from its Phase I study in December 2007. Following these positive results, Ablynx has initiated a Phase Ib multiple-dose study in May 2008, directly in the target patient population rather than healthy volunteers for ALX-0081.

Company website: www.ablynx.com

Back to top

©2011• Cellular and Molecular Immunology • Last update of this page on 15/9/2008